Data Sheet 3_Tumor microenvironment-activated ferritin nanovector enables enhanced tumor d

A PDF document describes a novel ferritin-derived nanomedicine platform, The-05, designed for tumor microenvironment-activated delivery of KRASG12C inhibitors and degraders. The study provides in vitro proof-of-concept for delivering Adagrasib and the PROTAC degrader LC-2 to KRAS-mutated non-small cell lung cancer and pancreatic ductal adenocarcinoma cellular models. The dataset was authored by Annalisa Pia Abbinantefina and last updated on March 17, 2026.

Use Cases

• Benchmarking drug delivery efficiency based on the described nanocarrier encapsulation and activation by MMP-2/9.
• Analyzing therapeutic outcomes for KRASG12C inhibitors like Adagrasib in described cellular models of NSCLC and PDAC.
• Studying mechanisms to overcome drug resistance based on the described platform's design to address limitations of Sotorasib and Adagrasib.

Strengths

• Dataset is openly licensed under CC-BY-4.0.
• The description provides a detailed scientific context for the nanomedicine platform and its targets.

Limitations

• The dataset is a 10.2 KB PDF, suggesting limited raw data or primary results.
• Row count and column-level documentation are absent; data structure must be inferred from the PDF.
• The description focuses on in vitro proof-of-concept; applicability to in vivo models is not yet demonstrated.

Provenance

Source

figshare, authored by Annalisa Pia Abbinantefina.

Collection Method

Likely contains experimental results from the described nanomedicine study.

Freshness

Last updated 2026-03-17 13:08:12.